Genzyme tested 4 compounds: a transgenic enzyme developed with Pharming; a CHO-based enzyme developed by Synpac; NZ-1001, an enzyme developed by Novazyme; and another CHO-based enzyme produced internally using existing Genzyme cell lines. In 2002, after comparing all four, the analysis showed that Genzyme’s CHO product offered the most promise from a clinical and manufacturing perspective. The company also discovered that making sufficient quantities of enzyme with the transgenic process or the Synpac cell line would be problematic. The company also decided to continue the development of NZ-1001 as a potential next-generation therapy for Pompe disease.
Novazyme's compound was a dud, Canfield was honest enough to admit* results were an artifact. But like yourself, I doubt it will be presented as a failure in the movie...
*Canfield answers a question in an IPA Conference back in Nov 2003:
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.